type 2 diabetes mellitus
Conditions
Interventions
None listed
Sponsors
Department of Endocrinology and Diabetes Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetic patient whose HbA1c(JDS) is more than or equal to 5.8 %. (HbA1c value at a registration differs from preceding test is less than 2.0%.) Patient indicated necessity of Alogliptin administration. Patient who is competent to understand the aim of this study and agree on it.
Exclusion criteria
Exclusion criteria: Patient taking medication of bone-building drug or medication that may highly likely influence bone turnover. Secondary osteoporosis. Patient taking another kind of DPP-4 inhibitor. Insulin-treated diabetic patient. Patient with a history of heart failure, liver dysfunction, severe liver disorder, severe kidney disorder. Patient during acute stage of bone fracture or therapy of malignancy. Patient with endocrine disorder, gastrointestinal disease or malignancy that may highly influence bone turnover. Drug abuser. Heavy user of alcohol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of bone mineral density and biochemical marker of bone metabolic turnover 4 months after administration of Alogliptin | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of physical findings, glucose metabolism, lipid metabolism, liver function and bone metabolism-related factors 4 months after administration of Alogliptin. | — |
Countries
Japan
Contacts
Public ContactShin Tsunekawa
Nagoya University Graduate School of Medicine Department of Endocrinology and Diabetes
Outcome results
None listed